Abstract:

Lysins or Lytic enzymes of Bacteriophage are highly evolved molecules produced to release their progeny by hydrolyzing the bacterial host cell wall. Now days, due to Multi Drug Resistance in many streptococcal infections; this mechanism is exploited as an alternative therapy against traditional antibiotic therapy. But in the treatment of phage therapy the mode of action is still unclear in the literatures. This study will evidence the probable mode of mechanism by the lysin in the breakage of host cell wall by In Silico approach. 3-D structure of Lysin was retrieved from Protein Data Bank and structure of peptidoglycan is retrieved from the PubChem. Docking studies was performed using Hex 6.3 taking lysin as receptor and peptidoglycan as ligand. Results were visualized in PyMol molecular visualization software. Docking studies showed the hydrophilic interaction between the peptidoglycan and lysin. The interacting residue of lysin belongs to CHAP domain which is responsible for the amidase catalytic activity which results in the breakage of cell wall for the release of their progeny. Molecular interactions between the lysin and peptidoglycan showed the possible mechanism for lysin which is responsible for breaking the major bonds in peptidoglycan layer for the release of bacteriophage progeny inside the host bacterial cell. This study will give the further evidence for the mode of action and by understanding this mechanism further improved therapies can be achieved in the Multi Drug Resistance bacterial infections.

Keywords: Bacteriophage, Streptococcus spp, Multi Drug Resistance bacterial infections, Lysin, Peptidoglycan, Docking studies.

References:

[1].     Berkowitz FE. Antibiotic resistance in bacteria. South Med J 1995;88:797-804.

[2].     B. Levin, J. Bull. Population and evolutionary dynamics of phage therapy. Nature Reviews Microbiology 2004; 2: 166-173.

[3].     Hermoso JA, Garcia JL, Garcia P. Taking aim on bacterial pathogens: From phage therapy to enzybiotics. Curr Opin Microbiol 2007; 10:461-472.

[4].     Navarre WW, Ton-That H, Faull KF, Schneewind O. Multiple enzymatic activities of the murein hydrolase from staphylococcal phage phi11. Identification of a D-alanyl –glycine endopeptidase activity. J Biol chem 1999; 274:15847-56.

[5].     Nelson D, Schuch R, Chahales P, Zhu S, Fischetti VA . PlyC: A multimeric bacteriophage lysine. Proc Natl Acad Sci USA 2006; 103:10765-70.

[6].     Pritchard DG, Dong S, Baker JR, Engler JA. The bifunctional peptidoglycan lysine of Streptococcus agalactiae bacteriophage B30. Microbiology 2004; 150:2079-87.

[7].     Stark CJ, Hoopes JT, Bonocora RP, Nelson DC. Bacteriophage lytic enzymes as antimicrobials. Bacteriophage in the Detection and control of Foodborne Pathogens, eds Sabour PV, Griffith MW (ASM Press, Washington DC), 2010. pp 137-156.

[8].     Smith H W, Huggins M B. Successful treatment of experimental E.coli infections in mice using phage; its superiority over antibiotics. J Gen Microbio. 1982; 128:307-318.

[9].     S. Matsuzaki, M. Rashel, J. Uchiyama, S. Sakurai, T. Ujihara, M. Kuroda, M. Ikeuchi,T. Tani, M. Fujieda, H.Wakiguchi, S. Imai, Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J. Infect. Chemother. 2005; 11: 211-219.

[10].  Tenover FC, Hughes JM. The challenges of emerging infectious diseases: development and spread of multiply resistant bacterial pathogens. JAMA 1996; 275:300-4.

[11].  VinodKumar C. S, Suneeta Kalsurmath, Neelagund Y.F. Utility of lytic bacteriophage in the treatment of multidrug resistant Pseudomonas aeruginosa septicemia in mice. Ind J Patho Microbiol 2008;51(3):360-366

[12].  VinodKumar C. S, Suneeta Kalsurmath, Neelagund Y.F. Bacteriophage in the treatment of experimental septicemic mice from a clinical isolate of multidrug resistant Klebsiella pneumoniae. J Commun Dis. 2005;37(3): 749-753

[13].  VinodKumar C. S, Srinivasa H, Basavarajappa K.G, Nitin Bandekar. Isolation of Bacteriophages for MRSA obtained from Diabetic foot- A Possible treatment Option in infections. Inter J Biotechnol Biochem. 2010; 6(5): 801-809.

[14].  VinodKumar C. S, Srinivasa H, Basavarajappa K.G, Geethalakshmi S, Nitin Bandekar. Isolation of Bacteriophages to MDR Enterococci obtained from Diabetic foot- A Novel antimicrobial agent waiting in the Shelf?. Ind J Pathol Microbiol. 2011;54(1):90-96

[15].  VinodKumar C. S, Srinivasa H, Basavarajappa K.G, Umakanth Patil, Nitin Bandekar, Rajashri Patil. Abrogation of Staphylococcus aureus wound infection by bacteriophage in diabetic rats. International journal of pharmacy and drug research. 2011:3(3); 202-207

[16].  VinodKumar C. S, Srinivasa H, Basavarajappa K.G, Umakanth Patil, Nitin Bandekar, Rajashri Patil. Effectiveness of bacteriophage in the treatment of Staphylococcus aureus wound infection in the diabetic animal model. Asian J Pharm Res. 2012;5: 123-127

[17].  Young R. Bacteriophage lysis: Mechanism and regulation. Microbial Rev 1992; 56:430-481.